Lung Cancer

Papers
(The H4-Index of Lung Cancer is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis106
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England80
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients71
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy66
175 External Validation of a Left Anterior Descending Coronary Artery Dose Constraint in Patients with Non-Small Cell Lung Cancer: An NI–HEART Analysis63
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer63
190 Localised non-small cell lung cancer: patient characteristics and radical radiotherapy outcomes according to KRAS mutation status61
251 Optimising engagement and addressing inequalities for patients using a Digital Behaviour Change Intervention in lung cancer prehabilitation: A mixed-methods study61
260 Second Primary Lung Cancer Cohort Study (SPORT)53
101 Treating advanced EGFR positive non-small cell lung cancer patients with Osimertinib - the University Hospital Plymouth experience52
107 Osimertinib Efficacy in Advanced NSCLC Patients with PACC and Classical-Like EGFR Mutations: A Retrospective Analysis from The Christie51
98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer51
74 The first-in-class PRX3 inhibitor RSO-021 modulates the composition of malignant pleural effusions by eliciting immunomodulation and decreasing epithelial to mesenchymal protein expression48
86 Real World Outcomes of Patients Receiving Neoadjuvant Treatment for Non-Small Cell Lung Cancer46
89 Why do almost half of our patients not complete 12 months of maintenance durvalumab after successful radical chemoradiotherapy?45
Contents44
Title Page44
Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study43
Cell pellet from fixative medium of transbronchial lung biopsy sample improves lung cancer ancillary test43
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma42
Frailty, comorbidity and cardiovascular risk assessment in older patients with lung cancer38
The first historical description of malignant mesotheliomas37
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours36
The role of mediastinoscopy following EBUS36
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study36
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes35
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study35
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study35
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed35
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study34
Clinical relevance of circulating activin A and follistatin in small cell lung cancer34
Author index33
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial33
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score33
0.10950112342834